TIDMPRTC
RNS Number : 6869F
PureTech Health PLC
19 July 2021
19 July 2021
PureTech Health plc
PureTech Founded Entity Gelesis, the Maker of Plenity(R), to
Become a Publicly Traded Company via Merger with Capstar Special
Purpose Acquisition Corp.
Public listing of Gelesis, along with Karuna Therapeutics
(Nasdaq: KRTX) and Vor Biopharma (Nasdaq: VOR), five other private
Founded Entities and advanced Wholly Owned Pipeline, further
exemplifies the success of PureTech's unique value-generating model
for developing new medicines
At Closing, Gelesis is expected to have a pro forma implied
market value of approximately $1.3 billion to support full
commercial launch of Plenity(R) for weight management and further
expand manufacturing capacity to meet demand
Transaction is expected to provide Gelesis with up to $376
million of gross proceeds, including $100 million PIPE anchored by
new and existing top tier investors and partners
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company announces that
its Founded Entity, Gelesis, Inc. ("Gelesis") and Capstar Special
Purpose Acquisition Corp. (NYSE: CPSR) ("Capstar"), have entered
into a definitive business combination agreement. Upon completion
of the transaction, the combined company's securities are expected
to be traded on the New York Stock Exchange (NYSE) under the symbol
"GLS."
"Upon completion of the transaction, Gelesis will be PureTech's
third publicly-traded Founded Entity. Based on the expected
valuation, Gelesis, along with Karuna and Vor, will have a combined
value of over $5.4 billion," said Eric Elenko, Chief Innovation
Officer at PureTech. "This is just another example of the unique
and multi-pronged model PureTech has created to advance meaningful
treatments for patients and drive future growth. We are very
pleased with the progress that has been made towards the broad
commercial launch of Plenity later this year and that Gelesis has
the resources to meet the increasing demand."
Gelesis and Capstar will host a joint investor conference call
to discuss the transaction today, July 19, 2021, at 8:30 a.m.
Eastern Time. A telephone replay of the call will be available
until July 29, 2021 via the same numbers, and a replay of the
webcast will be archived on the investor relations website.
The conference call can be accessed via webcast on Gelesis'
investor relations website at gelesis.com/investors, or by dialing
+1 844-512-2921 within the U.S. or +1 412-317-6671 for
international callers and entering the passcode 1145464.
The full text of the announcement from Gelesis is as
follows:
Gelesis, a Consumer-Focused Biotherapeutics Company and the
Maker of Plenity(R), to Become a Publicly Traded Company via Merger
with Capstar Special Purpose Acquisition Corp.
-- Building on the successful beta launch of its first product
Plenity(R), Gelesis aims to transform weight management. Gelesis
developed a novel biomimetic therapeutic platform that has yielded
Plenity and an advanced pipeline of therapeutic candidates for a
range of other gut-related disorders
-- Plenity makes it easier to eat less and feel fuller with
smaller portions and offers a new weight management solution for
over 150 million Americans, many of whom did not have a
prescription alternative before. Plenity is FDA-cleared to aid in
weight management in adults with excess weight or obesity, Body
Mass Index (BMI) of 25 to 40 kg/m(2), when used in conjunction with
diet and exercise
-- Pro forma implied market value of approximately $1.3 billion
and enterprise value of approximately $1.0 billion
-- Transaction is expected to provide Gelesis with up to $376
million of gross proceeds to fund the full commercial launch of
Plenity later this year and to expand manufacturing to meet demand,
including $100 million from a common stock PIPE financing at $10.00
per share anchored by new and existing top tier investors and
partners, including PIMCO private funds, Kennedy Lewis Investment
Management, Pritzker Vlock Family Office, China Medical Systems
Holdings Limited (CMS), and co-founder PureTech Health
BOSTON, MA & AUSTIN, TX, JULY 19, 2021 - Gelesis, Inc.
("Gelesis" or the "Company"), a biotherapeutics company advancing
biomimetic superabsorbent hydrogels to treat excess weight and
metabolic disorders, and Capstar Special Purpose Acquisition Corp.
(NYSE: CPSR) ("Capstar"), a special purpose acquisition company
sponsored by affiliates of Capstar Partners, LLC and certain
private funds managed by PIMCO, announced today that they have
entered into a definitive business combination agreement. Upon
completion of the transaction, the combined company's securities
are expected to be traded on the New York Stock Exchange (NYSE)
under the symbol "GLS."
A New Approach to Weight Management
Gelesis is a biotherapeutics company aiming to transform weight
management using a proprietary biomimetic superabsorbent hydrogel
technology. The Company's first commercial product, Plenity(R), is
a U.S. Food and Drug Administration (FDA) cleared aid in weight
management in adults with excess weight or obesity, Body Mass Index
(BMI) of 25 to 40 kg/m(2), when used in conjunction with diet and
exercise. Plenity has the broadest BMI range of any prescription
weight-management aid to date-over 150 million American adults
could be eligible for treatment with Plenity, many of whom did not
have a prescription alternative before. Plenity's unique scientific
approach and efficacy, safety and tolerability profile allow
Gelesis to bring it to market in a completely new way.
Plenity capsules contain a non-systemic biomimetic hydrogel that
is not absorbed but instead acts locally in the gastrointestinal
(GI) tract. The capsules are taken with water before meals and are
designed to help people feel satisfied with smaller meals. Plenity
combines the simplicity and convenience of a consumer product with
clinical and scientific validation as well as FDA regulatory
clearance as a de novo Class II medical device. In clinical
studies, 6 out of 10 adults had clinically meaningful weight loss
and those people lost on average, within six months, ten percent of
their body weight (about 22 lbs). There was no difference in
overall side effects compared to placebo. The most common side
effects were diarrhea, distended abdomen, infrequent bowel
movements and flatulence.
Plenity is a prescription product with a direct-to-patient
approach, giving the consumer the option of going through leading
telehealth platform Ro, or through an in-person healthcare provider
visit. This makes it easier for consumers to seek free physician
evaluation on their own time and their own terms. If prescribed,
the product is delivered to the consumer's home within two days at
a transparent cost of $98/month, or $1.75 per meal.
Plenity is now available in limited release, and over 48,000
members have begun their weight management journey. During
Plenity's beta launch in October 2020, with limited promotion and
without brand awareness marketing, Plenity surpassed all branded
prescription weight management products in new monthly members
during the month of testing, with high satisfaction ratings. The
Company anticipates the full commercial launch of Plenity later in
2021 and is currently constructing a larger manufacturing facility
to meet anticipated demand.
Gelesis' novel platform technology is inspired by the structural
and mechanical properties of raw vegetables. When consumed, the
hydrogel forms small solid gel pieces in the stomach consisting of
water held by a 3D cellulose structures, similar to raw vegetables.
The structures, which have no calories, are homogeneously mixed
with the ingested foods, increasing the volume and firmness of that
meal while reducing its caloric density. The hydrogel pieces are
not absorbed and partially degrade in the large intestine,
releasing the water before leaving the body naturally. In clinical
trials, this therapeutic approach demonstrated a strong efficacy
and safety profile.
Management Comments
"We are delighted to have found such a stellar group of partners
and investors as we expand the launch of the first and only
FDA-cleared and clinically validated prescription aid for weight
management that is available for the broadest range of the
population with excess weight, including even those who are
overweight without co-morbidities ," said Yishai Zohar, Founder and
CEO of Gelesis. "Capstar's leadership team has a track record of
successfully building known brands and tackling fundamental
consumer problems across a variety of industries. We look forward
to building on the exciting momentum of our beta launch with this
partnership and funding, and we are committed to making a
meaningful difference in the lives of millions of Americans seeking
scientifically proven and convenient options to manage their
weight."
"Yishai and the Gelesis team have developed a tremendous
solution that is poised to transform the weight management
industry," said Steve Hicks, the Chairman and CEO of Capstar. "We
raised our Capstar SPAC last year with the goal of finding a
high-growth, disruptive business that is helping people live a
better, healthier life. Gelesis fits that criteria perfectly and we
are elated to partner with them as they start their exciting next
leg of growth."
Transaction Overview
The transaction values the combined company at an implied
enterprise value of approximately $1.0 billion and equity value of
approximately $1.3 billion, based on a $10.00 per share price of
Capstar common stock and assuming no redemptions by Capstar's
public shareholders. The transaction will provide up to $376
million in gross proceeds to the combined company from a
combination of a $100 million common stock PIPE financing at $10.00
per share along with $276 million of cash held in Capstar's trust
account (assuming no redemptions by Capstar's public shareholders).
The PIPE financing is anchored by a mix of new and existing top
tier investors and partners, including PIMCO private funds,
Pritzker Vlock Family Office, China Medical Systems Holdings
Limited (CMS), and co-founder PureTech Health. Kennedy Lewis
Investment Management will invest $10 million in the PIPE
conditioned upon the closing of their $100 million senior secured
credit facility to the Company, which is subject to the completion
of due diligence, final documentation, and customary closing
conditions. Proceeds from the business combination, PIPE, and
credit facility will be primarily used to support the full
commercial launch of Plenity for weight management later this year
and expanded manufacturing to meet consumer demand. Gelesis'
existing shareholders will convert 100% of their ownership stakes
into the new company.
The transaction has been unanimously approved by the Boards of
Directors of both Gelesis and Capstar. It is expected to close in
the fourth quarter of 2021, subject to the satisfaction of certain
closing conditions, including a registration statement being
declared effective by the U.S. Securities and Exchange Commission
(the "SEC") and the approval of Capstar shareholders.
Additional information about the transaction, including a copy
of the business combination agreement and investor presentation,
will be provided in a Current Report on Form 8-K to be filed by
Capstar with the SEC and available at www.sec.gov .
Advisors
Citi is serving as exclusive financial advisor to Gelesis and
Goodwin Procter LLP is serving as legal counsel to Gelesis. UBS
Investment Bank is serving as exclusive financial and lead capital
markets advisor to Capstar and Kramer Levin Naftalis & Frankel
LLP is serving as its legal counsel. UBS Investment Bank and Citi
are serving as private placement agents to Capstar with respect to
the PIPE financing. Winston & Strawn LLP served as counsel to
the placement agents. BTIG, LLC is also serving as a capital
markets advisor to Capstar.
Conference Call Information
Gelesis and Capstar will host a joint investor conference call
to discuss the transaction today, July 19, 2021, at 8:30 a.m.
Eastern Time. A telephone replay of the call will be available
until July 29, 2021 via the same numbers, and a replay of the
webcast will be archived on the investor relations website.
The conference call can be accessed via webcast on Gelesis'
investor relations website at gelesis.com/investors, or by dialing
+1 844-512-2921 within the U.S. or +1 412-317-6671 for
international callers and entering the passcode 1145464.
Important Safety Information
-- Patients who are pregnant or are allergic to cellulose,
citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide
should not take Plenity.
-- To avoid impact on the absorption of medications:
o For all medications that should be taken with food, take them
after starting a meal.
o For all medications that should be taken without food (on an
empty stomach), continue taking on an empty stomach or as
recommended by your physician.
-- The overall incidence of side effects with Plenity was no
different than placebo. The most common side effects were diarrhea,
distended abdomen, infrequent bowel movements, and flatulence.
-- Contact a doctor right away if problems occur. If you have a
severe allergic reaction, severe stomach pain, or severe diarrhea,
stop using Plenity until you can speak to your doctor.
Rx Only. For the safe and proper use of Plenity or more
information, talk to a healthcare professional, read the Patient
Instructions for Use , or call 1-844-PLENITY.
About Gelesis
Gelesis is a consumer-centered biotherapeutics company advancing
a novel category of treatments for weight management and gut
related chronic diseases. Our non-systemic superabsorbent hydrogels
are inspired by the composition (i.e., water & cellulose) and
mechanical properties (e.g., elasticity or firmness) of raw
vegetables. They are conveniently administered in capsules to
create a much larger volume of small, non-aggregating hydrogel
pieces that become an integrated part of the meals, and act locally
in the digestive system. Our portfolio includes Plenity (R) , an
FDA-cleared product to aid in weight management, as well as
potential therapies in development for Type 2 Diabetes,
Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic
Steatohepatitis (NASH), and Functional Constipation. For more
information, visit gelesis.com , or connect with us on Twitter
@GelesisInc.
About Capstar Acquisition Corp.
Capstar Special Purpose Acquisition Corp. (NYSE: CPSR) is
sponsored by Capstar Sponsor Group, LLC, and is led by Chairman and
CEO, R. Steven Hicks. Capstar is a special purpose acquisition
company formed for the purpose of effecting a business combination
with one or more businesses in the consumer, healthcare and
technology, media and telecom industry (TMT) sectors.
Additional Information and Where to Find It
Capstar intends to file a Registration Statement on Form S-4
with the SEC, which will include a proxy statement/prospectus, that
will be both the proxy statement to be distributed to Capstar
shareholders in connection with its solicitation of proxies for the
vote by Capstar shareholders with respect to the proposed business
combination and other matters as may be described in the
Registration Statement, as well as the prospectus relating to the
issuance of certain securities to be issued in the proposed
business combination. After the Registration Statement is declared
effective, the proxy statement/prospectus and other relevant
documents will be sent to Capstar and Gelesis shareholders. Capstar
also will file other documents regarding the proposed transaction
with the SEC. This press release does not contain all the
information that should be considered concerning the proposed
business combination and is not intended to form the basis of any
investment decision or any other decision in respect of the
proposed business combination. Before making any voting decision,
Capstar's shareholders and other interested persons are advised to
read, when available, the preliminary proxy statement/prospectus
included in the Registration Statement, the amendments thereto and
the definitive proxy statement/prospectus and all other relevant
documents filed or that will be filed with the SEC in connection
with the proposed transaction as they become available because they
will contain important information about Gelesis, Capstar and the
proposed transaction.
When available, the definitive proxy statement/prospectus and
other relevant materials for the proposed business combination will
be mailed to shareholders of Capstar as of a record date to be
established for voting on the proposed business combination.
Investors and security holders will also be able to obtain free
copies of the Registration Statement, the proxy
statement/prospectus and all other relevant documents filed or that
will be filed with the SEC by Capstar, without charge, once
available, through the website maintained by the SEC at www.sec.gov
.
The documents filed by Capstar with the SEC also may be obtained
free of charge at Capstar's website at www.capstarspac.com , or by
written request to: Capstar Special Purpose Acquisition Corp., 405
West 14th Street, Austin, TX 78701, Attention: R. Steven Hicks,
Chief Executive Officer, (512) 340-7800.
Participants in the Solicitation
Capstar and its directors and executive officers may be deemed
participants in the solicitation of proxies from Capstar's
shareholders with respect to the proposed business combination. The
names of those directors and executive officers and a description
of their interests in Capstar is contained in Capstar's final
prospectus dated July 6, 2020 relating to its initial public
offering and in subsequent filings with the SEC, which are
available free of charge at the SEC's web site at www.sec.gov. To
the extent such holdings of Capstar's securities may have changed
since that time, such changes have been or will be reflected on
Statements of Changes in Beneficial Ownership on Form 4 filed with
the SEC. Additional information regarding the interests of such
participants will be contained in the proxy statement/prospectus
for the proposed business combination when available.
Gelesis and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the
shareholders of Capstar in connection with the proposed business
combination. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
business combination will be included in the proxy
statement/prospectus for the proposed business combination when
available.
Forward-Looking Statements
Certain statements, estimates, targets and projections in this
press release may constitute "forward-looking statements" within
the meaning of the federal securities laws. The words "anticipate,"
"believe," continue," "could," "estimate," "expect," "intend,"
"may," "might," "plan," "possible," "potential," "predict,"
"project," "should," "strive," "would" and similar expressions may
identify forward-looking statements, but the absence of these words
does not mean that statement is not forward looking.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Forward-looking statements include, but are not
limited to, statements regarding the satisfaction of closing
conditions to the proposed business combination and the expected
timing of the completion of the proposed business combination, the
benefits of the proposed business combination, the competitive
environment in which Gelesis operates, the expected future
operating and financial performance and market opportunities of
Gelesis and statements regarding Gelesis' and Capstar's
expectations, hopes, beliefs, intentions or strategies regarding
the future,. In addition, any statements that refer to projections,
forecasts, or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Gelesis and
Capstar assume no obligation and do not intend to update or revise
these forward-looking statements, whether as a result of new
information, future events, or otherwise. Gelesis and Capstar give
no assurance that any expectations set forth in this press release
will be achieved. Various factors could cause actual future
results, performance or events to differ materially from those
described herein. Some of the factors that may impact future
results and performance may include, without limitation: (i) the
size, demand and growth potential of the markets for Plenity(R),
Gelesis' other product candidates and its ability to serve those
markets; (ii) the degree of market acceptance and adoption of
Gelesis' products; (iii) Gelesis' ability to develop innovative
products and compete with other companies engaged in the weight
loss industry; (iv) Gelesis' ability to complete successfully the
full commercial launch of Plenity(R) and its growth plans,
including new possible indications and the clinical data from
ongoing and future studies about liver and other diseases; (v) the
inability of the parties to successfully or timely consummate the
proposed business combination, including the risk that any required
regulatory approvals are not obtained, are delayed or are subject
to unanticipated conditions that could adversely affect the
combined company or the expected benefits of the business
combination or that the approval of the shareholders of Capstar is
not obtained; (vi) the inability of Gelesis to obtain the secured
financing from Kennedy Lewis Investment Management; (vii) failure
to realize the anticipated benefits of the business combination,
including as a result of a delay or difficulty in integrating the
businesses of Capstar and Gelesis; (viii) the amount of redemption
requests made by Capstar shareholders; (ix) the ability of Capstar
or the combined company to issue equity or equity-linked securities
or obtain debt financing in connection with the proposed business
combination or in the future; (x) the outcome of any legal
proceedings that may be instituted against Capstar, Gelesis, the
combined company or others following the announcement of the
proposed business combination and any definitive agreements with
respect thereto; (xi) the ability to meet stock exchange listing
standards at or following the consummation of the proposed business
combination; (xii) the risk that the proposed business combination
disrupts current plans and operations of Gelesis as a result of the
announcement and consummation of the proposed business combination,
and as a result of the post-transaction company being a publicly
listed issuer; (xiii) the regulatory pathway for Gelesis' products
and responses from regulators, including the FDA and similar
regulators outside of the United States, (xiv) the ability of the
combined company to grow and manage growth profitably, maintain
relationships with customers and suppliers and retain Gelesis'
management and key employees; (xv) costs related to the proposed
business combination, including costs associated with the
post-transaction company being a publicly listed issuer; (xiv)
changes in applicable laws or regulations; (xvi) the possibility
that Gelesis or the combined company may be adversely affected by
other economic, business, regulatory and/or competitive factors;
(xvii) Gelesis' estimates of expenses and profitability; (xviii)
ongoing regulatory requirements, (xix) any competing products or
technologies that may emerge, (xx) the volatility of the telehealth
market in general, or insufficient patient demand; (xxi) the
ability of Gelesis to defend its intellectual property and satisfy
regulatory requirements; (xxii) the impact of the COVID 19 pandemic
on Gelesis' business; (xxiii) the limited operating history of
Gelesis; and (xxiv) those factors discussed in Capstar's final
prospectus dated July 6, 2020 and Annual Report on Form 10-K for
the fiscal year ended December 31, 2020 and the Registration
Statement, in each case, under the heading "Risk Factors" and other
documents of Capstar filed, or to be filed, with the SEC, including
the proxy statement/prospectus on Form S-4 relating to the proposed
business combination, which is expected to be filed by Capstar with
the SEC. These filings address other important risks and
uncertainties that could cause actual results and events to differ
materially from those contained in the forward-looking
statements.
Non-Solicitation
This press release relates to a proposed transaction between
Gelesis and Capstar. This press release is not a proxy statement or
solicitation of a proxy, consent or authorization with respect to
any securities or in respect of the proposed business combination
and shall not constitute an offer to sell or a solicitation of an
offer to buy the securities of Capstar, the Company or the combined
company, nor shall there be any sale of any such securities in any
state or jurisdiction in which such offer, solicitation, or sale
would be unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction. No offer of
securities shall be made except by means of a prospectus meeting
the requirements of the Securities Act of 1933, as amended.
-----
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two that have received FDA clearance and
European marketing authorization, as of the date of PureTech's most
recently filed Annual Report on Form 20-F. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Ownership Information
PureTech's percentage ownership of Gelesis as at June 30, 2021
was approximately 19.2 percent on a diluted basis, prior to the
transaction. This calculation of PureTech's holding includes issued
and outstanding shares as well as options and warrants to purchase
shares, but excludes unallocated shares authorized to be issued
pursuant to equity incentive plans. PureTech's ownership of Gelesis
will be updated following completion of the transaction. PureTech
has a right to royalty payments as a percentage of net sales from
Gelesis. PureTech has a right to royalty payments as a percentage
of net sales from Gelesis.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, expectations regarding Gelesis' merger with Capstar Special
Purpose Acquisition Corp., including expectations regarding the
completion of the transaction, expectations regarding the
commercial launch of Plenity(R), and those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these
forward-looking statements, whether as a result of new
information, future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDZGMNGLKGMZM
(END) Dow Jones Newswires
July 19, 2021 07:02 ET (11:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024